12 results about "Basilar membrane" patented technology

The invention discloses a preparation method of a cochlear organ chip integrated with a blood labyrinth barrier, and belongs to the field of biomedical engineering. The preparation method of the simulated blood labyrinth barrier comprises the following steps: constructing an endothelial cell culture cavity and a pericyte culture cavity, and separating the endothelial cell culture cavity and the pericyte culture cavity through a simulated basement membrane; and respectively inoculating percutaneous cells and endothelial cells into a percutaneous cell culture cavity and an endothelial cell culture cavity, and culturing to obtain the simulated blood lost barrier. The chip can effectively simulate the structure and the function of the BLB, and the barrier integrity of the BLB is evaluated through TEER (trans-epithelial electrical resistance) measurement and an apparent permeability coefficient. The invention also relates to application of the chip in NIHL drug screening, in particular to drug evaluation for oxidative stress induced inner ear organ injury. Through the platform, the protection effect of the candidate drugs on the TBHP-induced oxidative stress injury of the inner ear organs can be evaluated, and a new tool and thought are provided for developing novel NIHL treatment drugs.

Presented herein are systems and methods of providing acoustic stimulation to a human subject in order to evoke an auditory response. The method includes generating a chirp signal, where generating the chirp signal includes adding a plurality of frequency signals, each frequency signal being delayed in the chirp signal based on its associated frequency-specific basilar membrane delay, the frequency-specific basilar delay being determined as a function of an in-vivo frequency-specific basilar membrane delay.

This invention relates to the field of cochlear basilar membrane anatomy technology with integrated microscopic vision, and discloses an integrated microscopic cochlear basilar membrane anatomy instrument platform, including a fixing mechanism fixedly connected to the inner wall of the groove to reduce the height difference between the liquid and the outlet during liquid extraction. A storage mechanism rotatably connected to the inner wall of the fixing mechanism stores the liquid. A deceleration mechanism fixedly connected to the outer wall of the fixing mechanism slows down the movement speed of the device. This prevents hydrostatic pressure loss as the liquid level drops, which would result in insufficient initial force for the liquid to enter the outlet tube, slowing down the liquid delivery efficiency, preventing timely replenishment of the physiological solution, causing osmotic pressure imbalance in the sample, and ultimately deforming the sample, rendering it unusable.

The invention belongs to the technical field of medicine, and particularly provides application of clotrimazole in preparation of a medicine for preventing and relieving cisplatin toxicity, the clotrimazole is an artificially synthesized imidazole antifungal compound, and the purity of the clotrimazole is 99.97% or above; the protective effect of clotrimazole in hair cells and hair cell lines of cochlea basilar membranes cultured in vitro is verified through HEI-OC1 cell culture and C57 mouse basilar membrane culture, and the in-vivo effect of clotrimazole is verified through tympanic injection of C57 mice; besides, the research test of clotrimazole for mouse cis-platinum ear toxicity shows that hearing thresholds of all frequencies after cis-platinum treatment are obviously increased, ABR threshold offset caused by cis-platinum is reduced by injection of clotrimazole into tympanic chambers, hair cell loss of all gynaecology is greatly improved due to the protection effect of clotrimazole, and the cis-platinum ear toxicity of mice is improved. Finally, the clotrimazole is proved to have a remarkable effect on prevention or treatment of cisplatin toxicity.

The invention provides an automatic analysis method for severity of cochlea lost hydrops. The method comprises the following steps: acquiring a microscopic image of a certain animal cochlea pathology; preprocessing the microscopic image; automatically segmenting the cochlea structure of the preprocessed microscopic image; automatically extracting a cochlear tube contour surrounded by a vestibular membrane and a basilar membrane in a cochlea structure of the microscopic image and a structure contour on the cochlea basilar membrane, and manually correcting the extracted contours; and automatically calculating the ratio of S1 to S and obtaining the analysis result of the severity degree of cochlea lost hydrops based on the artificially corrected area S1 corresponding to the contour of the cochlea tube surrounded by the vestibular membrane and the basilar membrane and the area S corresponding to the contour of the structure on the cochlea basilar membrane. According to the method, the vacancy of quantitative analysis tools for cochlear hydrops is filled, the method serves for otology basic research and vestibular disease research, and more efficient and objective technical support is provided for mechanism research and treatment evaluation of inner ear diseases such as Meniere disease and the like.

The present application relates to the field of biophysics technology, especially to a kind of calculation method for considering the contribution of biological activity to human sensory function.It includes a new type of calculation analysis model for considering the motion of cochlear acoustic function key support structure of biological activity based on physical mechanics principle.The present application deduces the periodic variation of the stiffness of basilar membrane in space and time while coupled with lymphatic fluid motion equation, and is solved.I.e.develop a kind of calculation method for considering the contribution of biological activity to human sensory function, and the correctness of the analytical method is verified by computer numerical simulation.The method established by the present application is easy to operate, feasible, efficient and accurate.

This invention discloses a hair cell protectant based on a ferritin nanoplatform and its application in treating hearing loss, belonging to the field of biomedicine. The ferritin nanoparticles of this invention, loaded with cimicifugin, include ferritin (Fn) as a carrier and cimicifugin (Ci@Fn) loaded within the ferritin. By loading cimicifugin (Ci), an extract of cimicifugin, into ferritin, it is endowed with additional anti-inflammatory and tissue-protective functions, thereby achieving a more precise and effective therapeutic effect. After injection through the round window membrane (RWM) behind the ear, Ci@Fn is transported to the basement membrane along with the flow of perilymph and endolymph, ultimately targeting the inner ear hair cells (HCs). After entering the hair cells, Ci@Fn is taken up and degraded by lysosomes, releasing cimicifugin (Ci), thereby exerting a protective effect on the hair cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of neratinib in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the neratinib in preparation of the medicine for preventing and treating hearing impairment / deafness is provided. According to the invention, the fact that neratinib can play a hearing protection role by specifically regulating and controlling cochlea immune microenvironment is found for the first time, and the hearing protection role is specifically realized by the following mechanisms: regulating and controlling biological effects such as cell signal channels, inflammatory response and cell stress response, protecting hair cell structures, and reducing cochlea basilar membrane outer hair cell loss caused by noise exposure. Based on the new discovery of the invention, the neratinib can be used for preparing medicines for preventing and treating hearing impairment and deafness caused by noise.

Diagnosing and treating presbycusis (age related hearing loss) includes measuring basilar membrane stiffness. In an example, a low frequency component of an electrocochleogram stimulation signal is used to bias a region of the basilar membrane, the results of which are used basilar membrane stiffness. The resulting measurement is used to measure a subcomponent of presbycusis. Further, the measurement can be combined with known diagnostic methods to reveal or distinguish other origins of hearing loss such as strial presbycusis, sensory presbycusis, neural presbycusis, and cochlea conductive presbycusis. The relative contributions for each of the diagnosed origins of hearing loss can be determined.

The invention belongs to the field of biological medicines, and particularly relates to application of penicillamine in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the penicillamine in preparing the medicine for preventing and treating hearing impairment / deafness is provided. The hearing disorder and / or deafness is caused by noise. It is found for the first time that penicillamine can play a hearing protection role by specifically regulating a cochlea immune microenvironment, and the hearing protection role is specifically achieved through the following mechanisms: inhibition of T cell activation: interference of a TCR signal channel; the hair cell structure is protected; the cochlea basilar membrane outer hair cell loss caused by noise exposure is reduced. Based on the new discovery of the invention, the penicillamine can be used for preventing and treating hearing impairment and deafness caused by noise.

The application belongs to the technical field of gene therapy, and particularly relates to an AAV capsid protein mutant targeting glial cells and application thereof. The AAV capsid protein mutant is constructed by inserting a polypeptide with glial cell infection characteristics between N589 and R590 of an AAV-DJ capsid protein amino acid sequence, and exhibits enhanced transduction and targeting in inner ear basal membrane supporting cells, and has the function of enhancing supporting cell transduction in the cochlear basal membrane of newborn and adult mice, thereby being capable of solving the problem of low transduction efficiency of AAV in the cochlear basal membrane supporting cells of adult mice, and providing a potentially available tool for gene therapy of deafness genes positioned in supporting cells by Chen et al. GJB2 and the like.

The invention relates to a fully implanted artificial cochlea device based on a bionic basement membrane sensor, which comprises an ABM bionic array sensing module, a pre-amplifier, a filter, a gain amplifier, an implant stimulating electrode, a bias voltage feedback regulation module and an external interface, and is characterized in that the ABM bionic array sensing module comprises a plurality of narrow-band frequency ABM sensors; each ABM sensor only responds to acoustic excitation in a certain specific narrow-band frequency range, and each ABM sensor has a conjugate characteristic; the ABM bionic array sensing module, the implant stimulating electrode, the bias voltage feedback regulation module and the external interface form an EcochG feedback tracing module, and the EcochG feedback tracing module is used for obtaining and receiving CM signals generated when the implant stimulating electrode responds to stimulation of the external interface, so that optimal matching of the ABM sensors and the implant stimulating electrode is achieved. Compared with the prior art, the method has the advantages of being capable of improving auditory experience, feasibility and stability and the like.